- Home
- CWD vs CLDI Comparison
CWD vs CLDI Comparison
Compare CWD & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CWD | CLDI |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 9.2M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | CWD | CLDI |
|---|---|---|
| Price | $1.58 | $1.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 151.0K | 69.7K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,657,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $26.79 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.42 | $1.10 |
| 52 Week High | $48.00 | $19.20 |
Technical Indicators
Market Signals| Indicator | CWD | CLDI |
|---|---|---|
| Relative Strength Index (RSI) | 33.04 | 36.32 |
| Support Level | $1.42 | $1.41 |
| Resistance Level | $1.83 | $1.45 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 34.74 | 0.00 |
Price Performance
Historical ComparisonAbout CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.